Clinical trials: Capecitabine
- Drug or intervention Capecitabine
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pan-tumor
ONO-4538 Phase II Rollover Study (ONO-4538-98)
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
- Trial name
- NCT04566380
- Testing
- ONO-4538, oxaliplatin, S-1
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Brainstem Glioma
A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
This study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.
- Trial name
- NCT01118377
- Testing
- Capecitabine, Radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the…
- Trial name
- NCT04607421
- Testing
- Encorafenib, Cetuximab, Oxaliplatin
- Where
- 274 sites in United States, Argentina and 27 more
- Volunteers
- 841 people
- Sponsor
- Pfizer
Toxicity Due to Chemotherapy
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
The purpose of this study is to provide emergency treatment of adult and pediatric patients: Following a fluorouracil or capecitabine overdose regardless of the presence of symptoms or Who exhibit early-onset, severe or…
- Trial name
- NCT01432301
- Testing
- uridine triacetate
- Sponsor
- Wellstat Therapeutics
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with…
- Trial name
- NCT00700570
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Advanced Colorectal Carcinoma
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
This is a prospective, multicenter, open, randomized controlled Phase II clinical study to evaluate the efficacy and safety of intratumoral injection of OH2 combined with capecitabine for first-line maintenance of advanced…
- Trial name
- NCT05648006
- Testing
- OH2, Capecitabine, Bevacizumab
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Glioma
A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas
This single arm study will assess the maximum tolerated dose, and dose-limiting toxicities, of Xeloda administered concurrently with radiation therapy, in children with newly diagnosed diffuse intrinsic brain stem gliomas and…
- Trial name
- NCT00532948
- Testing
- capecitabine [Xeloda]
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer Metastatic, Colorectal Cancer Stage III
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
This is an early phase I, single-arm, open-label clinical study designed to evaluate the safety, tolerability, and feasibility of COLONYVAQ-CRC, a physics-aware, quantum-classical AI-guided personalized neoantigen peptide…
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV
- Trial name
- COLONYVAQ™-CRC (NCT07328087)
- Testing
- Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.